1.36
+0.02(+1.49%)
Currency In USD
| Previous Close | 1.34 |
| Open | 1.35 |
| Day High | 1.39 |
| Day Low | 1.33 |
| 52-Week High | 5.17 |
| 52-Week Low | 0.95 |
| Volume | 590,660 |
| Average Volume | 922,657 |
| Market Cap | 147.26M |
| PE | -0.8 |
| EPS | -1.71 |
| Moving Average 50 Days | 1.63 |
| Moving Average 200 Days | 1.91 |
| Change | 0.02 |
If you invested $1000 in Aclaris Therapeutics, Inc. (ACRS) since IPO date, it would be worth $123.64 as of April 28, 2025 at a share price of $1.36. Whereas If you bought $1000 worth of Aclaris Therapeutics, Inc. (ACRS) shares 5 years ago, it would be worth $1,096.77 as of April 28, 2025 at a share price of $1.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
GlobeNewswire Inc.
Apr 22, 2025 10:59 AM GMT
- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 - WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
GlobeNewswire Inc.
Mar 04, 2025 12:00 PM GMT
WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company w
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
GlobeNewswire Inc.
Feb 12, 2025 11:50 AM GMT
- Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company foc